A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer

Overview

Journal J Cancer Immunol (Wilmington)

Date 2024 Dec 23

PMID 39713022

Authors

Ricardo A Leon-Letelier

Yihui Chen

Riccardo Ballaro

Ehsan Irajizad

Kim-An Do

Anirban Maitra

Jianjun Zhang

C Max Schmidt

Johannes F Fahrmann

Affiliations

Soon will be listed here.

References

Zhang T, Gao G, Sakandar H, Kwok L, Sun Z . Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target. Front Nutr. 2022; 9:814269. PMC: 8885515. DOI: 10.3389/fnut.2022.814269. View

Shirasu H, Todaka A, Omae K, Fujii H, Mizuno N, Ozaka M . Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer Sci. 2018; 110(2):707-716. PMC: 6361560. DOI: 10.1111/cas.13883. View

Mirji G, Worth A, Bhat S, El Sayed M, Kannan T, Goldman A . The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol. 2022; 7(75):eabn0704. PMC: 9925043. DOI: 10.1126/sciimmunol.abn0704. View

Querio G, Antoniotti S, Geddo F, Levi R, Gallo M . Modulation of Endothelial Function by TMAO, a Gut Microbiota-Derived Metabolite. Int J Mol Sci. 2023; 24(6). PMC: 10054148. DOI: 10.3390/ijms24065806. View

Ye D, Guan K, Xiong Y . Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Trends Cancer. 2018; 4(2):151-165. PMC: 5884165. DOI: 10.1016/j.trecan.2017.12.005. View

Irajizad E, Kenney A, Tang T, Vykoukal J, Wu R, Murage E . A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med. 2023; 4(9):101194. PMC: 10518621. DOI: 10.1016/j.xcrm.2023.101194. View

Ohno E, Hirooka Y, Kawashima H, Ishikawa T, Kanamori A, Ishikawa H . Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. J Gastroenterol Hepatol. 2017; 33(1):320-328. DOI: 10.1111/jgh.13967. View

Yilmaz L, Borazan E, Aytekin T, Baskonus I, Aytekin A, Oztuzcu S . Increased UGT1A3 and UGT1A7 expression is associated with pancreatic cancer. Asian Pac J Cancer Prev. 2015; 16(4):1651-5. DOI: 10.7314/apjcp.2015.16.4.1651. View

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

10.

Singhi A, Koay E, Chari S, Maitra A . Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology. 2019; 156(7):2024-2040. PMC: 6486851. DOI: 10.1053/j.gastro.2019.01.259. View

11.

Yu B, Kumbier K . Veridical data science. Proc Natl Acad Sci U S A. 2020; 117(8):3920-3929. PMC: 7049126. DOI: 10.1073/pnas.1901326117. View

12.

Tayob N, Lok A, Do K, Feng Z . Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol. 2015; 14(3):469-475.e2. PMC: 4744807. DOI: 10.1016/j.cgh.2015.07.049. View

13.

. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402):207-14. PMC: 3564958. DOI: 10.1038/nature11234. View

14.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

15.

Dbouk M, Katona B, Brand R, Chak A, Syngal S, Farrell J . The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022; 40(28):3257-3266. PMC: 9553376. DOI: 10.1200/JCO.22.00298. View

16.

Overbeek K, Levink I, Koopmann B, Harinck F, Konings I, Ausems M . Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2021; 71(6):1152-1160. PMC: 9120399. DOI: 10.1136/gutjnl-2020-323611. View

17.

Gupta V, Sharma N, Durden B, Garrido V, Kesh K, Edwards D . Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Cancer Res. 2021; 81(15):4001-4013. PMC: 8338764. DOI: 10.1158/0008-5472.CAN-20-2562. View

18.

Borger D, Goyal L, Yau T, Poon R, Ancukiewicz M, Deshpande V . Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014; 20(7):1884-90. PMC: 4107454. DOI: 10.1158/1078-0432.CCR-13-2649. View

19.

Fraunhoffer N, Abuelafia A, Chanez B, Bigonnet M, Gayet O, Roques J . Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Commun (Lond). 2022; 42(11):1212-1216. PMC: 9648386. DOI: 10.1002/cac2.12365. View

20.

Wade A . The estimation of cholesterol sulphate and cholesterol glucuronide in plasma. Clin Chim Acta. 1970; 27(1):109-16. DOI: 10.1016/0009-8981(70)90382-7. View